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Objective: The goal of this retrospective study was to
analyze the incidence and outcome of invasive fungal
disease in a large cohort of pediatric patients after allo-
geneic stem cell transplant at Stanford University from
2005-2012 treated with modern antifungal prophylaxis. In
comparison with prior studies, this study is unique in
including prophylaxis with voriconazole and dosing in-
formation on antifungal prophylaxis, as well as the prev-
alence of transaminitis in this population and relation to
antifungal prophylaxis.
Patients and Methods: Data was analyzed for 152 pediatric
patients between the ages of 0-21 years who received
allogeneic stem cell transplantation for any diagnosis at
Stanford University between 2005 and 2012. Both related
and unrelated donors were used, including bone marrow,
cord blood, and peripheral blood stem cell sources. All
patients received antifungal prophylaxis, although the
speciﬁc medication used and dosing was at the discretion
of the treating physician. Patients were categorized as
having proven, probable, or possible fungal disease based
on the EORTC/MSG classiﬁcation. Rates of invasive fungal
disease and level of transaminitis were analyzed by type of
antifungal prophylaxis as well as dosing in milligrams per
kilogram.
Results: The overall mortality in this cohort was 29%. Of
those, 57% of the deaths were due to relapse, 20% due to
infectious complications (3 fungal, 3 sepsis, 2 viral, 1 toxo-
plasmosis), 16% due to organ failure, and 7% due to GVHD.
Twenty ﬁve patients were diagnosed with fungal disease
prior to transplant and these patients were excluded from
this analysis.
In the 127 patients with no prior history of fungal disease,
60% were on ﬂuconazole prophylaxis, 32% were on vor-
iconazole, 7% were on micafungin or caspofungin and 2%
were on amphotericin. Nine of these patients subsequently
developed proven or probable invasive fungal disease. Pa-
tients who developed invasive fungal disease had a signiﬁ-
cantly higher mortality rate (67%) compared with those who
did not (25%). However, these two groups did not differ on
type of antifungal prophylaxis, underlying diagnosis, donor
source, product used or age. There was no difference in level
of transaminitis based on type of antifungal prophylaxis
(voriconazole vs. ﬂuconazole) or dose used in milligrams per
kilogram.
Conclusions: In those patients who develop invasive
fungal disease after transplant, mortality has decreased
over time but remains substantial at 67%. This data did not
support the use of one antifungal over another for pro-
phylaxis of invasive fungal disease in pediatric patients.
Voriconazole and ﬂuconazole caused similar levels of
transaminitis.237
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Objective: The goal of this retrospective studywas to analyze
the outcome in pediatric patients with a history of fungal
disease prior to allogeneic stem cell transplant.
Patients and Methods: Data was collected on 152 pediatric
patients between the ages of 0-21 years who received an
allogeneic stem cell transplant for any diagnosis at Stanford
University between 2005 and 2012. Twenty ﬁve of these
patients had a history of fungal disease prior to transplant.
All of these patients received secondary antifungal prophy-
laxis, although the speciﬁc medication used and dosing was
at the discretion of the treating physician. Patients were
analyzed regarding mortality and rates of secondary fungal
disease. Fungal disease was classiﬁed as proven, probable, or
possible invasive fungal disease based on the EORTC/MSG
classiﬁcation.
Results: Only 2 of the 25 patients with prior fungal disease
developed probable or proven invasive fungal disease after
transplant. The ﬁrst patient was an 18 year old male with
relapsed AML who was diagnosed with fungal pneumonia
(culture positive for aspergillus and candida at an outside
hospital) three years prior to transplant. He subsequently
developed recurrent fungal pneumonia (culture positive
for 3 different species of aspergillus and non candida
albicans yeast) approximately 1 year after transplant. He
was non compliant with his antifungal prophylaxis after
discharge. This patient ultimately died of his fungal
infection.
The second patient was a 16 year old male with relapsed
AML who was diagnosed with pulmonary fungal infection
on pre-transplant evaluation. He underwent a lobectomy
prior to transplant with fungal hyphae visualized on
pathology, although cultures were negative. He was main-
tained on twice weekly liposomal amphotericin and daily
caspofungin after discharge. Despite this prophylaxis, he
developed pulmonary and ocular fungal disease with a
positive aspergillus galactomannan 8 months after trans-
plant. This patient ultimately died secondary to infection
and chronic GVHD.
Of the remaining 23 patients with a history of fungal
disease prior to transplant, 13 were diagnosed based on
pulmonary nodules only, 4 were diagnosed based on
abnormal imaging ﬁndings in multiple organs, and the
remaining 6 were diagnosed by microbiology or histologic
ﬁndings. These patients received prophylaxis as follows: 5
voriconazole alone, 8 amphotericin alone and 10 a com-
bination of antifungals. Mortality in this group was 26%,
and this was not signiﬁcantly different from the mortality
in patients with no history of fungal disease prior to
transplant.
Conclusions: With appropriate treatment and secondary
prophylaxis, it is possible for patients with a history of fungal
disease to undergo allogeneic stem cell transplant without a
recurrence of their fungal disease or an increase in mortality
rate.
